Found 6 matching trials
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
PHASE1In this Phase 2 study, mCRPC patients with PSMA positive scans who progress...
Status
Active Not Recruiting
Location
UC Davis Comprehensive Cancer Center
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
PHASE1AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of...
Status
Active Not Recruiting
Location
St. Vincent's Private Hospital
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
PHASE1This is a First-in-Human Phase IA/IB/II open label dose escalation study of...
Status
Active Not Recruiting
Location
Highlands Oncology Group
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
PHASE2This is a study to test the safety and efficacy with the combination of a n...
Status
Active Not Recruiting
Location
Cancer Treatment Centers of America, Phoenix. 403
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
PHASE3The goal of this Phase 3 clinical trial is to study the safety and efficacy...
Status
Active Not Recruiting
Location
XCancer/Dothan Hematology & Oncology - 1114
Gotistobart Long Term Extension (LTE) Study
PHASE3This LTE study will examine the long-term overall survival and safety of go...
Status
Enrolling By Invitation
Location
Texas Oncology - Fort Worth Cancer Center (USOR)